Selected research
Industry Research
Commercial Drug Procurement Industry Research Report 2026
Market perspective
The global Commercial Drug Procurement market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Commercial Drug Procurement market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Commercial Drug Procurement market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Commercial Drug Procurement market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Commercial Drug Procurement include Viseven, Bionical Emas, Almac, BMclinical, Myonex, McKesson, Parexel, Patheon and Clinigen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Commercial Drug Procurement market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Commercial Drug Procurement.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Commercial Drug Procurement Market by Company
Viseven
Bionical Emas
Almac
BMclinical
Myonex
McKesson
Parexel
Patheon
Clinigen
UPS Healthcare
Catalent
Endpoint Clinical
Signant Health
YPrime
Commercial Drug Procurement Segment by Type
Tender
Direct Procurement
Competitive Negotiation
Others
Commercial Drug Procurement Segment by Application
Life Sciences
Clinical Trials
Others
Commercial Drug Procurement Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Commercial Drug Procurement market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Commercial Drug Procurement and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Commercial Drug Procurement.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Commercial Drug Procurement companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tender
- Direct Procurement
- Competitive Negotiation
- Others
Applications
- Life Sciences
- Clinical Trials
- Others
Companies covered
- Viseven
- Bionical Emas
- Almac
- BMclinical
- Myonex
- McKesson
- Parexel
- Patheon
- Clinigen
- UPS Healthcare
- Catalent
- Endpoint Clinical
- Signant Health
- YPrime
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Commercial Drug Procurement by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tender
- 2.2.3 Direct Procurement
- 2.2.4 Competitive Negotiation
- 2.2.5 Others
- 2.3 Commercial Drug Procurement by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Life Sciences
- 2.3.3 Clinical Trials
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Commercial Drug Procurement Breakdown Data by Type
- 3.1 Global Commercial Drug Procurement Historic Market Size by Type (2021-2026)
- 3.2 Global Commercial Drug Procurement Forecasted Market Size by Type (2027-2032)
4 Commercial Drug Procurement Breakdown Data by Application
- 4.1 Global Commercial Drug Procurement Historic Market Size by Application (2021-2026)
- 4.2 Global Commercial Drug Procurement Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Commercial Drug Procurement Market Perspective (2021-2032)
- 5.2 Global Commercial Drug Procurement Growth Trends by Region
- 5.2.1 Global Commercial Drug Procurement Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Commercial Drug Procurement Historic Market Size by Region (2021-2026)
- 5.2.3 Commercial Drug Procurement Forecasted Market Size by Region (2027-2032)
- 5.3 Commercial Drug Procurement Market Dynamics
- 5.3.1 Commercial Drug Procurement Industry Trends
- 5.3.2 Commercial Drug Procurement Market Drivers
- 5.3.3 Commercial Drug Procurement Market Challenges
- 5.3.4 Commercial Drug Procurement Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Commercial Drug Procurement Players by Revenue
- 6.1.1 Global Top Commercial Drug Procurement Players by Revenue (2021-2026)
- 6.1.2 Global Commercial Drug Procurement Revenue Market Share by Players (2021-2026)
- 6.2 Global Commercial Drug Procurement Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Commercial Drug Procurement Head Office and Area Served
- 6.4 Global Commercial Drug Procurement Players, Product Type & Application
- 6.5 Global Commercial Drug Procurement Manufacturers Established Date
- 6.6 Global Commercial Drug Procurement Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Commercial Drug Procurement Market Size (2021-2032)
- 7.2 North America Commercial Drug Procurement Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Commercial Drug Procurement Market Size by Country (2021-2026)
- 7.4 North America Commercial Drug Procurement Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Commercial Drug Procurement Market Size (2021-2032)
- 8.2 Europe Commercial Drug Procurement Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Commercial Drug Procurement Market Size by Country (2021-2026)
- 8.4 Europe Commercial Drug Procurement Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Commercial Drug Procurement Market Size (2021-2032)
- 9.2 Asia-Pacific Commercial Drug Procurement Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Commercial Drug Procurement Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Commercial Drug Procurement Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Commercial Drug Procurement Market Size (2021-2032)
- 10.2 South America Commercial Drug Procurement Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Commercial Drug Procurement Market Size by Country (2021-2026)
- 10.4 South America Commercial Drug Procurement Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Commercial Drug Procurement Market Size (2021-2032)
- 11.2 Middle East & Africa Commercial Drug Procurement Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Commercial Drug Procurement Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Commercial Drug Procurement Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Viseven
- 12.1.1 Viseven Company Information
- 12.1.2 Viseven Business Overview
- 12.1.3 Viseven Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.1.4 Viseven Commercial Drug Procurement Product Portfolio
- 12.1.5 Viseven Recent Developments
- 12.2 Bionical Emas
- 12.2.1 Bionical Emas Company Information
- 12.2.2 Bionical Emas Business Overview
- 12.2.3 Bionical Emas Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.2.4 Bionical Emas Commercial Drug Procurement Product Portfolio
- 12.2.5 Bionical Emas Recent Developments
- 12.3 Almac
- 12.3.1 Almac Company Information
- 12.3.2 Almac Business Overview
- 12.3.3 Almac Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.3.4 Almac Commercial Drug Procurement Product Portfolio
- 12.3.5 Almac Recent Developments
- 12.4 BMclinical
- 12.4.1 BMclinical Company Information
- 12.4.2 BMclinical Business Overview
- 12.4.3 BMclinical Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.4.4 BMclinical Commercial Drug Procurement Product Portfolio
- 12.4.5 BMclinical Recent Developments
- 12.5 Myonex
- 12.5.1 Myonex Company Information
- 12.5.2 Myonex Business Overview
- 12.5.3 Myonex Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.5.4 Myonex Commercial Drug Procurement Product Portfolio
- 12.5.5 Myonex Recent Developments
- 12.6 McKesson
- 12.6.1 McKesson Company Information
- 12.6.2 McKesson Business Overview
- 12.6.3 McKesson Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.6.4 McKesson Commercial Drug Procurement Product Portfolio
- 12.6.5 McKesson Recent Developments
- 12.7 Parexel
- 12.7.1 Parexel Company Information
- 12.7.2 Parexel Business Overview
- 12.7.3 Parexel Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.7.4 Parexel Commercial Drug Procurement Product Portfolio
- 12.7.5 Parexel Recent Developments
- 12.8 Patheon
- 12.8.1 Patheon Company Information
- 12.8.2 Patheon Business Overview
- 12.8.3 Patheon Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.8.4 Patheon Commercial Drug Procurement Product Portfolio
- 12.8.5 Patheon Recent Developments
- 12.9 Clinigen
- 12.9.1 Clinigen Company Information
- 12.9.2 Clinigen Business Overview
- 12.9.3 Clinigen Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.9.4 Clinigen Commercial Drug Procurement Product Portfolio
- 12.9.5 Clinigen Recent Developments
- 12.10 UPS Healthcare
- 12.10.1 UPS Healthcare Company Information
- 12.10.2 UPS Healthcare Business Overview
- 12.10.3 UPS Healthcare Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.10.4 UPS Healthcare Commercial Drug Procurement Product Portfolio
- 12.10.5 UPS Healthcare Recent Developments
- 12.11 Catalent
- 12.11.1 Catalent Company Information
- 12.11.2 Catalent Business Overview
- 12.11.3 Catalent Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.11.4 Catalent Commercial Drug Procurement Product Portfolio
- 12.11.5 Catalent Recent Developments
- 12.12 Endpoint Clinical
- 12.12.1 Endpoint Clinical Company Information
- 12.12.2 Endpoint Clinical Business Overview
- 12.12.3 Endpoint Clinical Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.12.4 Endpoint Clinical Commercial Drug Procurement Product Portfolio
- 12.12.5 Endpoint Clinical Recent Developments
- 12.13 Signant Health
- 12.13.1 Signant Health Company Information
- 12.13.2 Signant Health Business Overview
- 12.13.3 Signant Health Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.13.4 Signant Health Commercial Drug Procurement Product Portfolio
- 12.13.5 Signant Health Recent Developments
- 12.14 YPrime
- 12.14.1 YPrime Company Information
- 12.14.2 YPrime Business Overview
- 12.14.3 YPrime Revenue in Commercial Drug Procurement Business (2021-2026)
- 12.14.4 YPrime Commercial Drug Procurement Product Portfolio
- 12.14.5 YPrime Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst